PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2.

PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2.
复制标题

DOI:
10.1038/nm.2122
复制
发表时间:
2010-05
期刊:
影响因子:
82.9
通讯作者:
--
中科院分区:
医学1区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

白血病和其他癌症拥有自我更新的干细胞,有助于维持癌症。癌症干细胞根除被认为是成功的抗癌治疗的关键。通过引入白血病相关单核细胞白血病锌指(MoZ)-TIF2融合蛋白诱导的急性髓系白血病(AML)模型,我们证明了通过去除白血病干细胞可以治愈AML。MoZ融合蛋白与PU.1相互作用,刺激巨噬细胞集落刺激因子受体(M-CSFR,又称CSF1R/c-FMS/CD115)的表达。对PU.1缺陷小鼠的分析表明,PU.1对于MoZ-TIF2建立和维持AML干细胞是必不可少的。高水平表达CSF1R的细胞(CSF1R高细胞),而不表达低水平CSF1R的细胞(CSF1Rlow/−细胞),显示出强大的白血病启动活性。使用由CSF1R启动子控制的表达药物诱导自杀基因的转基因小鼠,通过切除CSF1RHigh细胞治愈AML。CSF1R缺陷小鼠急性髓系白血病的诱导受到抑制。CSF1R抑制剂延缓了MoZ-TIF2诱导的白血病的进展。因此,CSF1R高表达细胞含有白血病干细胞,PU1介导的CSF1R表达上调可能是治疗Moz白血病的有用靶点。
Leukemias and other cancers possess self-renewing stem cells that help to maintain the cancer. Cancer stem cell eradication is thought to be critical for successful anti-cancer therapy. Using an acute myeloid leukemia (AML) model induced by introducing the leukemia-associated monocytic leukemia zinc finger (MOZ)-TIF2 fusion protein, we show here that AML can be cured by the ablation of leukemia stem cells. The MOZ-fusion proteins interacted with PU.1 to stimulate the expression of macrophage-colony stimulating factor receptor (M-CSFR, also called CSF1R/c-FMS/CD115). Analysis using PU.1-deficient mice demonstrated that PU.1 was essential for MOZ-TIF2 to establish and maintain AML stem cells. Cells expressing high levels of CSF1R (CSF1Rhigh cells), but not those expressing low levels of CSF1R (CSF1Rlow/− cells), showed potent leukemia-initiating activity. Using transgenic mice expressing a drug-inducible suicide gene controlled by the CSF1R promoter, AML was cured by ablation of the CSF1Rhigh cells. Induction of AML was suppressed in CSF1R-deficient mice. CSF1R inhibitors slowed the progress of MOZ-TIF2–induced leukemia. Thus, CSF1Rhigh cells contain leukemia stem cells, and the PU.1-mediated upregulation of CSF1R may be a useful therapeutic target for MOZ leukemia.
DOI: 10.1101/gad.1393106
发表时间: 2006-05-15
影响因子: 10.5
作者:
Katsumoto, Takuo;Aikawa, Yukiko;Kitabayashi, Issay
通讯作者: Kitabayashi, Issay
DOI: 10.1101/gad.1382606
发表时间: 2006-05-01
影响因子: 10.5
作者:
Thomas, T;Corcoran, LM;Voss, AK
通讯作者: Voss, AK
DOI: 10.1016/s1535-6108(03)00051-5
发表时间: 2003-03-01
期刊: CANCER CELL
影响因子: 50.3
作者:
Deguchi, K;Ayton, PM;Gilliland, DG
通讯作者: Gilliland, DG
DOI: 10.4161/cc.4.7.1788
发表时间: 2005-07-01
期刊: CELL CYCLE
影响因子: 4.3
作者:
Dewar, AL;Zannettino, ACW;Lyons, AB
通讯作者: Lyons, AB
DOI: 10.1182/blood-2006-08-041202
发表时间: 2007-05-01
期刊: BLOOD
影响因子: 20.3
作者:
Jin, Guang;Yamazaki, Yukari;Nakamura, Takuro
通讯作者: Nakamura, Takuro